Partnership Expansion Novelion Therapeutics has recently entered into partnerships with Recordati S.p.A and Amryt Pharma plc for the commercialization of their products in Japan and worldwide. These partnerships indicate potential sales opportunities through expanded market reach.

Diversified Product Portfolio With a diversified commercial portfolio that includes MYALEPT® and JUXTAPID®, Novelion Therapeutics offers a range of products for rare diseases. This diverse product range presents sales opportunities catering to varied medical needs.

High-Value Market Positioning Novelion Therapeutics holds a position in the market focusing on rare diseases, offering specialized treatments for niche conditions. This exclusive market positioning can attract high-value sales opportunities in the healthcare sector.

Experienced Leadership Team The appointment of experienced executives like Mr. Price as the CFO brings strategic financial expertise to Novelion Therapeutics. This leadership ensures a strong foundation for business growth and potential sales expansion.

Financial Stability Despite past financing of $50M and debt financing, Novelion Therapeutics showcases financial stability with ongoing investments in science and clinical development. This financial robustness supports sales initiatives and growth strategies.